Advancing the development of its oral SERD, WEE1 inhibitor and BCL-2 inhibitor product candidates Advancing the development of its oral SERD, WEE1 inhibitor and BCL-2 inhibitor product candidates

Excerpt from:
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh